KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Amortizatization of Intangibles (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Amortizatization of Intangibles for 13 consecutive years, with -$45.8 million as the latest value for Q4 2025.

  • Quarterly Amortizatization of Intangibles fell 2009.09% to -$45.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$8.5 million through Dec 2025, down 121.22% year-over-year, with the annual reading at $7.5 million for FY2025, 31.25% down from the prior year.
  • Amortizatization of Intangibles for Q4 2025 was -$45.8 million at Halozyme Therapeutics, down from $17.8 million in the prior quarter.
  • The five-year high for Amortizatization of Intangibles was $27.2 million in Q3 2022, with the low at -$48.7 million in Q4 2023.
  • Average Amortizatization of Intangibles over 5 years is $5.5 million, with a median of $14.6 million recorded in 2022.
  • The sharpest move saw Amortizatization of Intangibles skyrocketed 104.92% in 2024, then crashed 2009.09% in 2025.
  • Over 5 years, Amortizatization of Intangibles stood at $741000.0 in 2021, then surged by 1090.82% to $8.8 million in 2022, then crashed by 651.98% to -$48.7 million in 2023, then surged by 104.92% to $2.4 million in 2024, then plummeted by 2009.09% to -$45.8 million in 2025.
  • According to Business Quant data, Amortizatization of Intangibles over the past three periods came in at -$45.8 million, $17.8 million, and $17.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.